Fresenius Medical Care

Startseite
Deutschland
Bad Homburg
Fresenius Medical Care

We are the world's leading provider of products and services for individuals with renal diseases.

We are the world’s leading provider of products and services
for individuals with renal diseases. We aim to create a future worth living for chronically and critically ill patients – worldwide and every day. We want to go a step further towards our vision by addressing the renal care continuum and with the help of critical care solutions and complementary assets. Thanks to our decades of experienc

e in dialysis, our innovative research and our value-based care approach, we can help our patients to enjoy the very best quality of life. Our portfolio encompasses a comprehensive range of high-quality health care products and services as well as various
dialysis treatment options for both in-center and home dialysis that are individually tailored to our patients’ needs.

29/05/2026

Our ERA 2026 landing page is now live on our website. Explore how Fresenius Medical Care will contribute to the 63rd European Renal Association (ERA) Congress in Glasgow, June 3–6, with new research and scientific exchange across key areas in kidney care, including hemodiafiltration, home dialysis, and artificial intelligence.

Visit our website to discover our accepted abstracts, poster presentations, oral sessions, and more – and find more information on where to connect with our teams on site during the congress.

We’re looking forward to seeing you there!

Visit our website here: https://freseniusmedicalcare.com/en/media/events/era-2026/?utm_source=facebook&utm_medium=organic_social&utm_campaign=29may2026_era_landingpage&utm_content=corporate

28/05/2026

When unexpected challenges arise, having support can make all the difference.

After a severe storm caused significant damage to Jessica’s home, she and her family were suddenly living in a hotel while navigating repairs and trying to maintain a sense of normalcy for their children.

During this difficult time, Jessica’s supervisor encouraged her to apply for the CARES Fund, Fresenius Medical Care’s employee hardship fund, which helped to provide immediate relief.

“The CARES Fund has been a blessing to me and my family when needed the most, and I am truly grateful for it,” Jessica shared. “That’s what it’s there for, to help. And if you need help, let them help.”

The support helped to cover temporary housing, replace lost food after a power outage, and provide stability while repairs were underway. Most importantly, it gave Jessica and her family peace of mind during an incredibly stressful time.

At Fresenius Medical Care, we’re people caring for people: not only for our patients, but for one another. Stories like Jessica’s reflect the care and commitment that make our culture so meaningful.

Interested in being part of a team that cares? Explore opportunities with us: Jobs.FreseniusMedicalCare.com

28/05/2026

News 📢: Today, Fresenius Medical Care is launching the first tranche of up to EUR 600 million under its new share buyback program, which has a total volume of around EUR 1 billion. The first tranche is expected to be completed by December 15, 2026.

The share buyback program is part of FME’s capital allocation framework, complementing dividends and reflecting FME’s commitment to disciplined, value-focused capital management.

Read more in today’s press release: https://freseniusmedicalcare.com/en/media/newsroom/fresenius-medical-care-launches-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million/?utm_source=facebook&utm_medium=organic_social&utm_campaign=28may2026_sbbfirsttranche_pressrelease&utm_content=corporate

27/05/2026

Our teams at Fresenius Medical Care are looking forward to joining the European Renal Association (ERA) 2026, June 3–6 in Glasgow, where our Global Medical Office and The Renal Research Institute (RRI) will present new research highlighting ongoing innovation in kidney care.

This year’s spotlight includes advancements in applying artificial intelligence (AI) and real-world evidence to support patient-centered outcomes across dialysis modalities, alongside new hemodiafiltration (HDF) research reinforcing the importance of evidence-based and personalized care.

We will also preview kinexus, a unified digital platform designed to support home dialysis programs by connecting remote therapy management and operational workflows within one integrated ecosystem.

Visit us at Booth # C.210 and RRI Booth # C.410 to learn more about our integrated portfolio of products and services supporting patients across the dialysis care pathway.

For more information, read the press release: https://freseniusmedicalcare.com/en/media/newsroom/fresenius-medical-care-highlights-new-renal-research-and-innovation-at-era-congress-2026/?utm_source=facebook&utm_medium=organic_social&utm_campaign=27may2026_era_pressrelease&utm_content=corporate

26/05/2026

News 📢: Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased ex*****on over 12 months, following the successful completion of the previous share buyback program at the end of April 2026.

The new share buyback program is based on the authorization to purchase and use treasury shares granted during Fresenius Medical Care’s Annual General Meeting on May 21, 2026. The program is expected to begin in the near future.

Our CEO, Helen Giza, said, “The new share buyback program reflects our unwavering commitment to create value and return capital to shareholders. Launching a new share buyback program shortly after successfully completing our initial EUR 1 billion share buyback – ahead of schedule – demonstrates our financial strength and disciplined ex*****on.”

Read more in today’s press release: https://freseniusmedicalcare.com/en/media/newsroom/fresenius-medical-care-announces-new-share-buyback-program-with-a-total-volume-of-around-eur-1-billion-with-phased-ex*****on-over-12-months/?utm_source=facebook&utm_medium=organic_social&utm_campaign=26may2026_newsbb_pressrelease&utm_content=corporate

22/05/2026

How do we move beyond diffusion alone to improve the outcomes for patients on dialysis?

In our latest Research in Brief, Karin Bergling, MD, PhD, from the Renal Research Institute (RRI), and Peter Blankestijn, MD, PhD, from the University Medical Center Utrecht, discuss clinical perspectives on two convection-enhancing therapies: online hemodiafiltration (HDF) and medium cut-off (MCO) dialyzers.

The clinical and patient-reported outcome evidence for online HDF is strong – especially at convection volumes exceeding 23 liters – while data on MCO dialyzers is scarce. The takeaway: These findings support a shift toward more personalized dialysis prescriptions.

Watch the full interview now and read the article to learn more: https://freseniusmedicalcare.com/en/media/multimedia/videos/research-in-brief-online-hemodiafiltration-and-medium-cut-off-dialyzers?utm_source=facebook&utm_medium=organic_social&utm_campaign=22_may_2026_rib_hdf_mco_dialyzers

22/05/2026

Yesterday, we concluded Fresenius Medical Care’s Annual General Meeting 2026. Thank you to our shareholders and to everyone who joined us – either live from the Congress Center in Frankfurt or virtually.

The meeting included updates on our performance, strategic priorities, and the road ahead, along with speeches from the Chair of our Supervisory Board, Michael Sen, and our CEO, Helen Giza.

If you missed the AGM, you can watch the webcast here: https://en.vistream.online/hv-freseniusmedicalcare-2026-oeffentlich?utm_source=facebook&utm_medium=organic_social&utm_campaign=22may2026_agm_webcast&utm_content=corporate

21/05/2026

Today, we held our 2026 Annual General Meeting at the Congress Center Messe in Frankfurt, Germany.

It was an important moment to look back on a strong year – shaped by the launch of our FME Reignite in June 2025 and by the culmination of our multi-year effort to fundamentally strengthen our Company as part of our FME25 turnaround and transformation.

In their speeches, Michael Sen, Chair of the Supervisory Board, and Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care, emphasized a clear message: by delivering on our key commitments, Fresenius Medical Care strengthened its competitiveness and resilience.

Our shareholders expressed strong support. With 78.71% of share capital represented, a dividend of €1.49 per share was approved, representing a 3% year over year increase. They also acknowledged the successful completion of our share buyback program and approved a new authorization, reflecting continued confidence in our financial strength and supporting our capital allocation framework, which includes further share buyback programs.

With these outcomes, Fresenius Medical Care is well positioned for continued earnings growth in 2026 and beyond. All agenda items were approved.

Thank you to our colleagues around the world – your dedication made another successful year possible.

👉 Read the full AGM 2026 voting results and press release: https://freseniusmedicalcare.com/en/media/newsroom/annual-general-meeting-strengthening-performance-and-advancing-innovation-in-kidney-care/?utm_source=facebook&utm_medium=organic_social&utm_campaign=21may2026_agm_pressrelease&utm_content=corporate

20/05/2026

The Supervisory Board of Fresenius Medical Care today has reappointed Martin Fischer, Chief Financial Officer and Member of the Management Board, for a period of five years until 2031.

Michael Sen, Chairman of the Supervisory Board, said, “Over the past few years, Martin Fischer has made a significant contribution to driving forward the transformation of Fresenius Medical Care. We are therefore very pleased that he will continue to serve the company.”

Read the press release: https://freseniusmedicalcare.com/en/media/newsroom/chief-financial-officer-martin-fischer-reappointed/?utm_source=facebook&utm_medium=organic_social&utm_campaign=20may2026_cforeappointed

20/05/2026

Preparations are in full swing for Fresenius Medical Care’s Annual General Meeting 2026. We look forward to welcoming our shareholders for tomorrow’s event.

Join us live at 10:00 CET from the Congress Center Messe in Frankfurt, Germany, to hear from Michael Sen, Chair of the Supervisory Board, and Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care.

Those attending virtually can tune in via our website to follow the speeches live: https://freseniusmedicalcare.com/en/investors/agm/?utm_source=facebook&utm_medium=organic_social&utm_campaign=20may2026_agm_behindthescenes

Adresse

Else-Kroener-Str. 1
Bad Homburg
61352

Telefon

+4961726090

Webseite

http://www.freseniusmedicalcare.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Fresenius Medical Care erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.